BridgeBio Pharma, Inc. (BBIO)

Executive Summary

BridgeBio Pharma is a Palo Alto, California-based commercial-stage biopharmaceutical company that discovers and develops medicines for genetic diseases, using a decentralized "hub-and-spoke" model where program-specific "spoke" teams are supported by centralized "hub" functions. Roughly ten years old, BridgeBio has grown into a large-cap biotech with a market capitalization of about $13.4 billion and trailing-twelve-month revenue of approximately $713 million (up 202% year over year), driven by its first approved commercial product. The company is not yet profitable but has guided to a path to profitability by 2027 as its pipeline of late-stage genetic-disease therapies matures.

Core Business Model & How They Work

BridgeBio makes money through direct product sales of approved medicines, license agreements that hand commercialization rights to partners in exchange for upfront and milestone payments, and royalties on partner net sales. Its operating model is built to run many rare/genetic-disease drug programs in parallel cheaply: management cites an average cost of roughly $40 million per program to reach proof-of-concept and about $10 million to reach an IND filing, achieved by centralizing regulatory, clinical, and commercial infrastructure ("hub") while giving each disease program ("spoke") focused, accountable teams. The company also holds minority equity stakes in spun-out entities (GondolaBio, BridgeBio Oncology Therapeutics) that let it retain economic exposure to earlier-stage or adjacent programs without funding them entirely off its own balance sheet.

Business Segments

BridgeBio does not break out traditional industry segments; instead its business is best understood as a portfolio of disease-specific programs at different stages: commercial products, Phase 3 near-term value drivers, and earlier Phase 1/2 and preclinical programs.

Product Portfolio

• Attruby (acoramidis) — FDA-approved November 2024 for transthyretin amyloid cardiomyopathy (ATTR-CM); generated $362.4 million in U.S. net product revenue in 2025 across ~7,800 patients, with a label claiming near-complete TTR stabilization and an estimated U.S. addressable population of 240,000 patients.
• Beyonttra (acoramidis, ex-U.S.) — approved in the EU, UK, Japan, and Switzerland, commercialized via partners Bayer (Europe) and Alexion (Japan); generated $105.0 million in license/services revenue plus $11.4 million in royalties in 2025, with over 50% new-brand prescription share in Germany within its first year.
• Nulibry (fosdenopterin) — approved for ultra-rare molybdenum cofactor deficiency; commercialization now handled by Sentynl Therapeutics.
• Truseltiq (infigratinib) — previously approved for cholangiocarcinoma; accelerated approval was withdrawn in May 2023.
• Late-stage pipeline: infigratinib for achondroplasia (Phase 3 PROPEL 3 met all endpoints, NDA/MAA planned H2 2026; >$5B market opportunity), encaleret for ADH1 (Phase 3 CALIBRATE met primary endpoint, FDA submission planned H1 2026), and BBP-418 for LGMD2I/R9 (Phase 3 FORTIFY interim success, FDA submission planned H1 2026).
• Earlier-stage: infigratinib for hypochondroplasia, encaleret for chronic hypoparathyroidism, BBP-812 gene therapy for Canavan disease, and a preclinical ATTR-CM antibody depleter program.

Competitive Landscape

In ATTR-CM, Attruby/Beyonttra compete against Pfizer's established Vyndaqel/Vyndamax franchise and Alnylam's newly approved vutrisiran, alongside a pipeline of RNAi, antisense, antibody, and gene-editing candidates from other developers. In achondroplasia, infigratinib would compete with BioMarin's already-approved Voxzogo (vosoritide), as well as pipeline candidates from Ascendis Pharma (TransCon CNP), Tyra Biosciences (TYRA-300), and Ribomic. Several of BridgeBio's rarer-disease programs (ADH1, LGMD2I/R9, Canavan disease) currently face limited or no approved competition, giving it potential first-mover advantage if approved.

Strategic Strengths & Risks

Strengths: a validated, capital-efficient R&D engine with strong genetic rationale behind each program; a large, growing IP estate (200+ issued patents, 300+ pending); a first significant commercial launch (Attruby) proving out the model; and multiple near-term Phase 3 readouts/approvals that could diversify revenue beyond ATTR-CM. Risks: continued net losses (-$691.9 million TTM) and reliance on Attruby/Beyonttra ramping fast enough to fund the rest of the pipeline; intense, well-funded competition in its largest market (ATTR-CM) from Pfizer and Alnylam; patent expirations in the early-to-mid 2030s for acoramidis and infigratinib; complete reliance on third-party contract manufacturers with no in-house manufacturing; and typical binary clinical/regulatory risk across its Phase 2/3 pipeline.

Financial Overview

Market cap ≈ $13.37 billion; TTM revenue ≈ $713.1 million (+202.4% YoY); net income ≈ -$691.9 million TTM; EPS ≈ -$3.57; ~195.5 million shares outstanding; no dividend. The revenue growth reflects Attruby's 2025 launch ramp and the Beyonttra partnership payments.

Summary Conclusion

BridgeBio has transitioned from a clinical-stage genetic-disease platform to a commercial biopharma company on the strength of Attruby's ATTR-CM launch, with several more potential approvals (achondroplasia, ADH1, LGMD2I/R9) queued for 2026. The thesis depends on continued commercial execution against well-capitalized competitors and successful conversion of its late-stage pipeline into approved, reimbursed products before cash burn becomes a constraint.